Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Barr, PM, Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (19 more authors) (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 129 (19). pp. 2612-2615. ISSN 0006-4971

Abstract

Metadata

Authors/Creators:
  • Barr, PM
  • Brown, JR
  • Hillmen, P https://orcid.org/0000-0001-5617-4403
  • O'Brien, S
  • Barrientos, JC
  • Reddy, NM
  • Coutre, S
  • Mulligan, SP
  • Jaeger, U
  • Furman, RR
  • Cymbalista, F
  • Montillo, M
  • Dearden, C
  • Robak, T
  • Moreno, C
  • Pagel, JM
  • Burger, JA
  • Suzuki, S
  • Sukbuntherng, J
  • Cole, G
  • James, DF
  • Byrd, JC
Dates:
  • Published: 11 May 2017
  • Accepted: 20 March 2017
  • Published (online): 3 April 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 25 Aug 2017 09:42
Last Modified: 25 Aug 2017 09:42
Status: Published
Publisher: American Society of Hematology
Identification Number: https://doi.org/10.1182/blood-2016-12-737346
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics